Clinical success and quality of life with brimonidine 0.2% or Timolol 0.5% used twice daily in glaucoma or ocular hypertension: A randomized clinical trial

Journal of Glaucoma

Volumn 9, Issue 3, 2000, Pages 224-234

  Javitt, J C ^a   Schiffman, R M ^a   Atlas, W ^a   Baum, K J ^a   Cookem, D L ^a   DuBiner, H B ^a   Katz, J L ^a   Kupin, T ^a   Memmen, J E ^a   Mundorf, T K ^a   Nelson, E ^a   Offenberg, H ^a   Schenker, H I ^a   Sharpe, E ^a   Stevenson, D ^a   Stewart, W C ^a   Tanchel, N ^a   Whitaker, R ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Alphagan; Brimonidine; Clinical effectiveness; Glaucoma Disability Index; Quality of life; Timolol; Timoptic

Indexed keywords

BRIMONIDINE; TIMOLOL MALEATE;

ADULT; ARTICLE; CHRONOTROPISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVALUATION; EYE BURN; FEMALE; GLAUCOMA; HEALTH SURVEY; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 0034445222     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-200006000-00005     Document Type: Article

References (37)

1. Adverse respiratory and cardiac events attributed to Timoptol eye solution, 1978-1985
2. Adverse effects experienced by patients taking timolol
3. Systemic effects of medications used to treat glaucoma
4. Adverse reactions from timolol administration
5. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker
6. Systemic adverse effects of topical ophthalmic agents. Implications for older patients
7. Randomized controlled trials and naturalistic data: Time for a change?
8. Drug evaluation: Brimonidine
9. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension
10. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial
11. 12-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in glaucoma or ocular hypertension patients
12. Twice-daily brimonidine tartrate 0.2% vs. Timolol 0.5%: 1-year results in glaucoma patients
13. A comparison of the safety and efficacy of twice-daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
14. The MOS short-form General Health Survey. Reliability and validity in a patient population
15. Measuring the impact of glaucoma and its treatment on quality of life: The Glaucoma Disability Index
16. Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma
17. Assessing the validity of the SF-36 General Health Survey
18. Is the SF-36 Health Survey questionnaire suitable as a self-report measure of the health status of older adults with Parkinson's disease?
19. The ocular hypertension treatment study
20. Validation of a questionnaire for comparing the tolerability of ophthalmic medications
21. On the combination of independent two-sample tests of Wilcoxon
22. A network of algorithm for performing Fisher's exact test in rXc contingency tables
23. Exercise metabolism and beta-blocker therapy. An update
24. Brimonidine 0.2% versus betaxolol 0.25% as measured by the clinical success rate and quality of life effects in patients with glaucoma or ocular hypertension
25. Adverse pulmonary effects of topical β blockers used in the treatment of glaucoma
26. Topical timolol decreases plasma high-density lipoprotein cholesterol level
27. Changes in depressive status associated with topical beta-blockers
28. Medical treatment of glaucoma - A reappraisal of the risks
29. Asthma in the elderly patient
30. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents
31. Catecholamines, sympathomimetic drug, and adrenergic receptor antagonists
32. Preclinical evaluation of brimonidine
33. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine